News

Healthtech Startup Avammune Bags $12 Mn From Capital 2B, Others

Publications

Small molecule innate immune modulators in cancer therapy
Avijit Goswami, Sandeep Goyal, Princy Khurana, Kawaljit Singh, Barnali Deb, Aditya Kulkarni

PMID: 39318624 PMCID: PMC11419979 DOI:10.3389/fimmu.2024.1395655

AVA-ADR-001 Suppresses Tumor Growth and Induces Anti-tumor Immunity by Selectively Inhibiting ADAR1 p150
Aditya Kulkarni, Avijit Goswami, Barnali Deb, Ankita Mohanty, Sandeep Goyal, Kawaljit Singh, Rahul Yadav, Princy Khurana, Narenkumar Muralidharan, Jan Rehwinkel

Molecules 2022,27(19), 6721; DOI: 10.3390/molecules27196721

Conference Abstracts

Abstract 3095: Development of a novel ADAR1 inhibitor as a potent immunomodulator for the treatment of solid tumors
Aditya Kulkarni, Avijit Goswami, Sandeep Goyal, Kawaljit Singh, Princy Khurana, Ishani Ghoshal

Journal: Cancer Research Cancer Res (2023) 83 (7_Supplement): 3095. https://doi.org/10.1158/1538-7445.AM2023-3095

1335 AVA-NP-695 potently and selectively inhibits ENPP1 to activate STING pathway and abrogate tumor metastasis in 4T1 breast cancer syngeneic mouse model
AdityaKulkarni, Avijit Goswami, Sandeep Goyal, Princy Khurana, Arun Papaiah

Journal for ImmunoTherapy of Cancer Nov 2022, 10 (Suppl 2) A1386; DOI:10.1136/jitc-2022-SITC2022.1335

Reach out to us

→

USA

Avammune Therapeutics, Inc. Pennsylvania

India

Avammune Lifesciences Private Limited #545/6, 1st Floor, Devarachikkanahalli Main Road, Bommanahalli, Bangalore 560068
080-41268499
© 2026 Avammune Therapeutics